CLINICAL_TRIALS ClinicalTrials.gov record update

An Open-label Phase 1/2 Multicentre Study to Evaluate the Safety, Tolerability and Efficacy of RTX001 Autologous Macrophages in Participants With Liver Cirrhosis Who Have Hepatic Decompensation (EMERALD)

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT06823713
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:28:33.247457+00:00
Published At: 2026-01-28T00:00:00+00:00
Record Updated At: 2026-01-28
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["End-stage Liver Disease (ESLD)", "Cirrhosis, Liver", "Cirrhosis, Decompensated", "Liver Diseases", "Fibrosis and Cirrhosis of Liver", "Decompensated Liver Cirrhosis", "Decompensated Cirrhosis", "Steatotic Liver Disease"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2026-01-28"
protocolSection.identificationModule.nctId: "NCT06823713"
protocolSection.identificationModule.officialTitle: "An Open-label Phase 1/2 Multicentre Study to Evaluate the Safety, Tolerability and Efficacy of RTX001 Autologous Macrophages in Participants With Liver Cirrhosis Who Have Hepatic Decompensation (EMERALD)"
protocolSection.statusModule.overallStatus: "RECRUITING"
protocolSection.designModule.phases: ["PHASE1", "PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.